MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-05-2026
Bioventus Interest Expense 2011-2026 | BVS
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Bioventus
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.45 M | 1.64 M | 1.29 M | -9.77 M | -1.46 M | 4.43 M | 75 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.43 M | -9.77 M | -750 K |
Quarterly Interest Expense Bioventus
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -79 K | -561 K | -777 K | 626 K | -159 K | -63 K | -494 K | -513 K | 1.59 M | - | -115 K | -604 K | 363 K | - | -757 K | -1.64 M | -419 K | - | 3.28 M | 1.34 M | -2.46 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.28 M | -2.46 M | -80.6 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biomerica
BMRA
|
367 | $ 2.16 | 1.41 % | $ 4.96 M |  USA |
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Biodesix
BDSX
|
8.26 M | $ 15.54 | 5.79 % | $ 2.02 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 16.34 | 0.06 % | $ 494 M | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 83.59 | -1.54 % | $ 10.5 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 101.28 | 0.93 % | $ 8.35 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 570.21 | -1.43 % | $ 45.9 B | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 74.24 | -1.97 % | $ 5.01 B | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 460.74 | 0.83 % | $ 13.3 B | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.61 | -1.07 % | $ 427 M | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 17.44 | -0.4 % | $ 390 M | USA |
 |
Pacific Biosciences of California
PACB
|
14.8 M | $ 1.39 | - | $ 417 M | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
Personalis
PSNL
|
24 K | $ 7.78 | 2.23 % | $ 461 M | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
RadNet
RDNT
|
32.1 M | $ 59.87 | -3.03 % | $ 4.5 B | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Senseonics Holdings
SENS
|
-23 K | $ 6.66 | 0.6 % | $ 278 M | USA |
 |
Sotera Health Company
SHC
|
8.55 M | $ 13.84 | -0.32 % | $ 3.93 B | USA |
 |
Soleno Therapeutics
SLNO
|
110 K | $ 31.34 | -1.2 % | $ 1.59 B | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 159.19 | 0.75 % | $ 7.89 B | USA |
 |
IQVIA Holdings
IQV
|
729 M | $ 166.09 | -0.52 % | $ 28.6 B | USA |
 |
Neuronetics
STIM
|
716 K | $ 1.46 | -9.06 % | $ 96.3 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
5.9 M | $ 1.18 | -19.18 % | $ 6.43 M | USA |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 264.46 | 2.05 % | $ 26.1 B |  Schweiz |
 |
Interpace Biosciences
IDXG
|
-394 K | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 125.98 | 1.77 % | $ 20 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 47.49 | 6.72 % | $ 2.84 B | USA |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
Precipio
PRPO
|
-1 K | $ 26.6 | -1.23 % | $ 34.5 M | USA |
 |
Celcuity
CELC
|
2.11 M | $ 102.01 | -4.44 % | $ 4.02 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 266.12 | 0.64 % | $ 22.1 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
ENDRA Life Sciences
NDRA
|
-691 K | $ 3.46 | -0.57 % | $ 1.86 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 7.86 | -2.96 % | $ 1.01 B | USA |
 |
Natera
NTRA
|
9.32 M | $ 194.52 | -2.78 % | $ 19.1 B | USA |